Point72 Hong Kong LTD Bristol Myers Squibb CO Call Options Transaction History

Point72 Hong Kong LTD

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $18,278 - $10.8 Million	140,600 Added 1026.28%	154,300 $11 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $18,278 - $10.8 Million	140,600 Added 1026.28%	154,300 $11 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $232,384 - $255,936	3,200 Added 30.48%	13,700 $1.06 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $4.68 Million - $5.61 Million	-76,100 Reduced 87.88%	10,500 $767,000
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $2.58 Million - $3.01 Million	48,100 Added 124.94%	86,600 $5.4 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $710,040 - $831,720	12,000 Added 45.28%	38,500 $2.28 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $1.46 Million - $1.59 Million	-23,600 Reduced 47.11%	26,500 $1.77 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $1.6 Million - $1.8 Million	26,900 Added 115.95%	50,100 $3.16 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $1.34 Million - $1.52 Million	23,200 New	23,200 $1.44 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.